Company news
Seastar Medical Holding Corporation (NASDAQ:ICU) news
Seastar Medical Holding Corporation news releases on 6ix. Latest, May 15, 2023: SeaStar Medical Reports First Quarter 2023 Financial Results and Provides…
Press releases — page 3
SeaStar Medical Reports First Quarter 2023 Financial Results and Provides a Business Update
May 14, 2023
SeaStar Medical Provides Regulatory Update Related to its HDE Application for Pediatric Selective Cytopheretic Device
May 8, 2023
SeaStar Medical Announces Activation of First Clinical Site in Pivotal Trial with Selective Cytopheretic Device in Critically Ill Adults with Acute Kidney Injury
April 18, 2023
SeaStar Medical Reports 2022 Financial Results and Provides a Business Update
March 29, 2023
SeaStar Medical Holding Corporation Closes Initial $3.3 Million Tranche of $9.8 Million Private Placement
March 15, 2023
SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury
February 14, 2023
SeaStar Medical to Hold Business Update Conference Call on February 15, 2023
February 13, 2023
SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury
February 8, 2023
SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients
January 8, 2023
SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI)
December 28, 2022
SeaStar Medical Bolsters Operational Expertise with Appointment of Thomas R. Mullen as Vice President of Operations and Product Development
December 1, 2022
SeaStar Medical Appoints Rick Barnett as Chairman of the Board of Directors
November 28, 2022
SeaStar Medical’s Lead Product Candidate, the Selective Cytopheretic Device (SCD), Included in Consensus Statement for Pediatric Acute Kidney Injury in First Pediatric Acute Disease Quality Initiative (ADQI) Meeting
November 6, 2022
SeaStar Medical (Nasdaq: ICU) Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children
November 2, 2022
SeaStar Medical Completes Business Combination with LMF Acquisition Opportunities
October 27, 2022
LMF Acquisition Opportunities, Inc. Stockholders Approve Previously Announced Business Combination with SeaStar Medical, Inc.
October 17, 2022
LMF Acquisition Opportunities and SeaStar Medical Announce Effectiveness of Registration Statement and Special Meeting of Stockholders to be Held October 18, 2022 to Approve Business Combination
September 27, 2022
SeaStar Medical Appoints Dr. Sai Prasad Iyer, Ph.D as VP, Medical Affairs and Clinical Development
September 18, 2022
SeaStar Medical Reports First Successful Treatment of Pediatric Patient with Hemophagocytic Lymphohistiocytosis (HLH) and Multi-Organ Failure with its SCD
July 31, 2022
LMF Acquisition Opportunities, Inc. Announces Extension of Deadline to Complete Business Combination
July 28, 2022
SeaStar Medical Submits Humanitarian Device Exemption Application to FDA for Use of Selective Cytopheretic Device in Children with Acute Kidney Injury
July 19, 2022
SeaStar Medical Announces Publication of Clinical Trial Results Demonstrating its SCD Significantly Lowered Mortality Rates among Critically Ill ICU COVID-19 Patients by Safely and Effectively Stopping Inflammation Causing Cytokine Storms
June 6, 2022
SeaStar Medical Appoints Kevin Chung, MD as Chief Medical Officer
May 23, 2022
SeaStar Medical Granted FDA Breakthrough Device Designation for a Novel Immunomodulatory Therapy for Acute Kidney Injury Patients
May 2, 2022